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Background: Randomized trials have demonstrated that drug eluting stents (DES) reduce the risk of target vessel revascularization (TVR) 
compared to bare metal stents (BMS). This benefit is less pronounced as artery diameter increases. Whether DES are superior to BMS for larger 
coronary arteries in the setting of routine clinical practice is unknown. The purpose of this study is to compare the safety and effectiveness of DES 
compared to BMS in patients within the NHLBI Dynamic Registry having PCI of arteries > 3.5 mm diameter.
Methods: We analyzed data from 869 patients undergoing de novo lesion PCI with reference vessel diameter greater than or equal to 3.5mm 
in wave 2, 4 and 5 of the NHLBI Dynamic Registry according to whether they were treated with DES or BMS. Patients with cardiogenic shock, 
concomitant intervention on arteries smaller than 3.5mm or sapheneous vein graft intervention were excluded. Patients were followed for 3 years for 
the occurrence of cardiovascular events.
Results: Compared to BMS patient (n=299), patients with DES (n=570) had a higher prevalence of hypertension (75.1% v. 60.7%, P<0.001), 
hyperlipidemia (75.6% vs. 56.5%, P<0.001), renal disease (9.5% vs. 2.3%, P<0.001) and previous coronary intervention (22% vs. 11.4%, P<0.001). 
At 3 year follow-up, the rate of unadjusted mortality was similar (8.6% in DES group vs. 9% in BMS group, p=0.76). There was a trend of excess MI 
at 3 year in DES group. (7.8% in DES group vs. 3.9% in BMS, p=0.05). Rates TVR at 3-years were similar and low in both groups (4.4% vs. 3.7%, 
p=0.62). After adjustment for differences in baseline characteristics, the adjusted hazard ratio for 3-year MI for DES was 1.85 (95% C.I. 0.93-3.7, 
p=0.08), for TVR at 3 years 1.14 (95% C.I. 0.52-2.49, p=0.75) and for mortality 0.89 (95%C.I. 0.49-1.62, p=0.71)
Conclusions: In our study of the unrestricted use of DES for patients with lesions in larger diameter coronary arteries, DES did not reduce 3-year 
risk of TVR. Although there was a trend of more MI in patients treated with DES, it was not significant after adjustment. These findings do not support 
the preferred use of DES over BMS for patients with lesions located in arteries >3.5mm.
